Search results
Results from the WOW.Com Content Network
A parasympathomimetic drug, sometimes called a cholinomimetic drug [1] or cholinergic receptor stimulating agent, [2] is a substance that stimulates the parasympathetic nervous system (PSNS).
An International Nonproprietary Name (INN) is an official generic and nonproprietary name given to a pharmaceutical substance or an active ingredient, [1] encompassing compounds, peptides and low-molecular-weight proteins (e.g., insulin, hormones, cytokines), as well as complex biological products, such as those used for gene therapy. [2]
Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs.In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. [1]
Zasocitinib (TAK-279, NDI-034858) is a drug which is an orally active, highly selective, allosteric tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various inflammatory conditions including psoriasis , psoriatic arthritis and Crohn's disease .
The following partial list contains marks which were originally legally protected trademarks, but which have subsequently lost legal protection as trademarks due to abandonment, non-renewal or improper issuance (the generic term predated the registration). Some marks retain trademark protection in certain countries despite being generic in others.
This is the first class of non-opioid pain medication approved to treat moderate to severe acute pain approved by the FDA in more than 20 years. The U.S. Food and Drug Administration (FDA) on ...
The term "me-too drug" or "follow-on drug" refers to a medication that is similar to a pre-existing drug, usually by making minor modifications to the prototype, reflected in slight changes in the profiles of side effects or activity, and used to treat conditions for which drugs already exist.
Firazorexton (INN Tooltip International Nonproprietary Name; development code TAK-994) is an experimental orexin 2 (OX 2) receptor agonist first described in a 2019 patent filed by Takeda Pharmaceutical Company. [1] [2] Firazorexton was studied by Takeda for the treatment of narcolepsy.